RecruitingPhase 1NCT06476808

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

Sponsor

Bristol-Myers Squibb

Enrollment

240 participants

Start Date

Sep 6, 2024

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer (NSCLC)High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This early-phase study tests BMS-986463, an experimental cancer drug, in patients with advanced solid tumors. Researchers are testing different doses to find the safest and most effective amount to give. **You may be eligible if...** - You have an advanced cancer (solid tumor) that has not responded to standard treatments - Your overall health is good enough to participate (ECOG 0 or 1, meaning you are fully active or restricted only in strenuous activity) - You have at least one tumor that can be biopsied before treatment **You may NOT be eligible if...** - Your cancer has spread to the membranes around your brain (leptomeningeal metastases) - You have another active cancer being treated - You had radiation therapy within the past 2 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986463

Specified dose on specified days

Locations(17)

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States

Valkyrie Clinical Trials

Los Angeles, California, United States

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States

Local Institution - 0045

Columbus, Ohio, United States

Local Institution - 0046

Dallas, Texas, United States

Local Institution - 0049

Houston, Texas, United States

BC Cancer Vancouver

Vancouver, British Columbia, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Local Institution - 0036

Bordeaux, Aquitaine, France

Local Institution - 0031

Villejuif, Val-de-Marne, France

Local Institution - 0035

Lyon, France

Local Institution - 0033

Milan, Italy

Local Institution - 0032

Milan, Italy

Local Institution - 0042

Barcelona, Barcelona [Barcelona], Spain

Local Institution - 0041

Avda.Pio XII 36,, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06476808

Related Trials

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT0714001615 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497254 locations

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037204 locations

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754156 locations